Blueprint
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of October 2017
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
02 October 2017 15:00 BST
 
Transparency Directive
Voting Rights and Capital
 
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 September 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,913,842 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,913,842.
 
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 
Media Relations
 
 
 
Esra Erkal-Paler
 
UK/Global
+44 203 749 5638
Karen Birmingham
 
UK/Global
+44 203 749 5634
Rob Skelding
 
UK/Global
+44 203 749 5821
Matt Kent
 
UK/Global
+44 203 749 5906
Jacob Lund
 
Sweden
+46 8 553 260 20
Michele Meixell
 
US
+1 302 885 2677
 
 
 
Investor Relations
 
 
 
Thomas Kudsk Larsen
 
 
+44 203 749 5712
Craig Marks
 
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
 
Oncology
+44 203 749 5797
Mitchell Chan
 
Oncology
+1 240 477 3771
Christer Gruvris
 
Diabetes; Autoimmunity, Neuroscience & Infection
+44 203 749 5711
Nick Stone
 
Respiratory; Brilinta
+44 203 749 5716
US toll free
 
 
+1 866 381 7277
 
 
Adrian Kemp
Company Secretary, AstraZeneca PLC
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 02 October 2017
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary